ReviewPharmaceutics2022
Amorphization of Drugs for Transdermal Delivery-a Recent Update.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 45 citations in OpenAlex.
- A drug-drug co-amorphous formulation for enhanced solubility and transdermal absorption of rotundine.International journal of pharmaceutics: X · 2026Article
- Amorphous Solid Dispersion Hydrogel Platform for Transdermal Delivery of Cannabidiol with Therapeutic Potential for Dermatitis.Pharmaceutics · 2026Article
- Amorphous Solid Dispersions of Polyphenols: Current State of the Art (Part I).Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Self-healable Hydrogel for Co-delivery of Hot-Melt Extruded System With Curcumin and Hesperetin Intended for Topical Application.AAPS PharmSciTech · 2025Article
- Innovative Wound Healing Strategy Through Amorphization of Active Pharmaceutical Ingredients as an Effective Approach for Hydrogel Formulation.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Solute-Vehicle-Skin Interactions and Their Contribution to Pharmacokinetics of Skin Delivery.Pharmaceutics · 2025Review
- Development of Rapidly Dissolving Microneedles Integrated with Valsartan-Loaded Nanoliposomes for Transdermal Drug Delivery: In Vitro and Ex Vivo Evaluation.Pharmaceutics · 2025Article
- Development of propranolol loaded SLN for transdermal delivery:Therapeutic delivery · 2025Article
- Supramolecular nanofibers of natural asiaticoside for self-supporting gelation and enhanced transdermal delivery.Frontiers in bioengineering and biotechnology · 2025Article
- Development of Transdermal Drug Delivery Approaches to Combat Diabetes: An Update.Current drug metabolism · 2025Review
- Article
- Penetration Enhancer-Free Mixed Micelles for Improving Eprinomectin Transdermal c Efficiency in Animal Parasitic Infections Therapy.International journal of nanomedicine · 2024Article
- Crisaborole-Enthused Glycerosomal Gel for an Augmented Skin Permeation.Recent advances in drug delivery and formulation · 2024Article
- Potentials of ionic liquids to overcome physical and biological barriers.Advanced drug delivery reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amorphous solid dispersion is a popular formulation approach for orally administered poorly water-soluble drugs, especially for BCS class II. But oral delivery could not be an automatic choice for some drugs with high first-pass metabolism susceptibility. In such cases, transdermal delivery is considered an alternative if the drug is potent and the dose is less than 10 mg. Amorphization of drugs causes supersaturation and enhances the thermodynamic activity of the drugs. Hence, drug transport through the skin could be improved. The stabilization of amorphous system is a persistent challenge that restricts its application. A polymeric system, where amorphous drug is dispersed in a polymeric carrier, helps its stability. However, high excipient load often becomes problematic for the polymeric amorphous system. Coamorphous formulation is another approach, where one drug is mixed with another drug or low molecular weight compound, which stabilizes each other, restricts crystallization, and maintains a single-phase homogenous amorphous system. Prevention of recrystallization along with enhanced skin permeation has been observed by the transdermal coamorphous system. But scalable manufacturing methods, extensive stability study and in-depth in vivo evaluation are lacking. This review has critically studied the mechanistic aspects of amorphization and transdermal permeation by analyzing recent researches in this field to propose a future direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.